Trial reportPost reproductive health2015
Intravaginally applied oxytocin improves post-menopausal vaginal atrophy.
Trial report in Post reproductive health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05627791 (Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman: A Randomized Placebo-controlled Trial
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Efficacy of Hormonal and Non-Hormonal Vaginal Gel Preparations on the Female Sexual Satisfaction Index in Postmenopausal Women with Sexual Dysfunction Syndrome:Sultan Qaboos University medical journal · 2025Pooled it
- Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review.Neuroscience and biobehavioral reviews · 2020Pooled it
- The effect of intra-vaginal oxytocin on sexual function in breastfeeding mothers: a randomized triple-blind placebo-controlled trial.BMC pregnancy and childbirth · 2022Trial
- Effects of oxytocin versus promestriene on genitourinary syndrome: a pilot, prospective, randomized, double-blind study.Clinics (Sao Paulo, Brazil) · 2022Trial
- Trial
- The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial.BMC women's health · 2020Trial
- Current and future pharmacotherapy for female sexual dysfunction.Nature reviews. Urology · 2026Review
- Oxytocin in growth, reproduction, restoration and health.Comprehensive psychoneuroendocrinology · 2024Review
- Sexual health promotion interventions in Iranian postmenopausal women: A systematic review of randomized controlled trials.Journal of education and health promotion · 2024Review
- Does activation of oxytocinergic reward circuits postpone the decline of the aging brain?Frontiers in psychology · 2023Review
- Non-oestrogenic modalities to reverse urogenital aging.Przeglad menopauzalny = Menopause review · 2021Review
- Hormonal Approach for Postmenopausal Vulvovaginal Atrophy.Frontiers in reproductive health · 2021Review
- Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (VagivitalMedical devices (Auckland, N.Z.) · 2020Article
- Time to advocate for better science, and better treatments for women.Menopause (New York, N.Y.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the efficacy of local oxytocin for the treatment of post-menopausal vaginal atrophy.
designDouble-blinded randomised controlled trial.
settingHealthy post-menopausal women in Stockholm, Sweden.
participantsSixty four post-menopausal women between February and June 2012 at the Karolinska University Hospital Huddinge/Sweden.
main outcome measuresThe efficacy of oxytocin for treatment of vaginal atrophy after seven weeks and cytological evaluation.
resultsThe percentage of superficial cells in the vaginal smears and the maturation values were significantly increased after seven weeks of treatment with vagitocin 400 IU (p = 0.0288 and p = 0.0002, respectively). The vaginal pH decreased significantly after seven weeks of treatment with vagitocin 100 IU (p = 0.02). The scores of vaginal atrophy, according to the histological evaluation, were significantly reduced after administration of vagitocin 100 IU (p = 0.03). The thickness of the endometrium did not differ between the treatment and placebo groups after seven weeks of treatment. The symptom experienced as the most bothersome was significantly reduced after seven weeks of treatment in the women receiving vagitocin 400 IU compared to women in the placebo group (p = 0.0089).
conclusionsTreatment with intravaginally applied oxytocin could be an alternative to local estrogen treatment in women with post-menopausal vaginal atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.